Literature DB >> 9029105

Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59.

M B Powell1, K J Marchbank, N K Rushmere, C W van den Berg, B P Morgan.   

Abstract

We have previously described the isolation and cloning of the rat analogue of the human complement inhibitor CD59 (hCD59). Using the rat CD59 (rCD59) coding region as probe, we have isolated positive cDNAs from a mouse kidney cDNA library. Sequence analysis of these clones indicated that they contained an open reading frame encoding a 124 amino acid protein. Comparisons with the known sequences of hCD59 and rCD59 suggested that the clones contained a full-length cDNA encoding the mouse analogue of CD59 (mCD59). The cDNA encoded a 81-bp 5'-flanking region, a 23 amino acid NH2-signal peptide, a 101 amino acid coding region including putative N-glycosylation sites and a glycosyl phosphatidylinositol (GPI) anchoring signal, and approximately 0.8 kb 3'-untranslated flanking region. Reverse transcriptase PCR revealed the presence of mCD59 mRNA in all mouse tissues examined. The gene for mCD59 was mapped by fluorescence in situ hybridization to the E2-E4 region of mouse chromosome 2, a region that includes areas syntenous with the location of the human CD59 gene on chromosome 11p13. Expression of mCD59 in a CD59-negative human cell line conferred protection against lysis by complement from rodent, human, and several other species, confirming that mCD59 was the functional analogue of hCD59 and that function was not species restricted. The expressed protein was glycosyl phosphatidylinositol anchored as demonstrated by its partial removal from U937 cells on treatment with phosphatidylinositol-specific phospholipase C. Abs raised against the expressed protein demonstrated the presence of mCD59 on all mouse blood cell types and on several mouse cell lines and neutralized function of mCD59 on mouse E and expressed on U937. Western blot analysis revealed that both expressed and endogenous mCD59 had a molecular mass of 22 to 24 kDa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Molecular basis for a link between complement and the vascular complications of diabetes.

Authors:  J Acosta; J Hettinga; R Flückiger; N Krumrei; A Goldfine; L Angarita; J Halperin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

3.  Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.

Authors:  Kelly N Ma; Siobhan M Cashman; J Harry Sweigard; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-04       Impact factor: 4.799

4.  Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison.

Authors:  Claire L Harris; S Melanie Hanna; Masashi Mizuno; Dewi S Holt; Kevin J Marchbank; B Paul Morgan
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

5.  Molecular and functional analysis of mouse decay accelerating factor (CD55).

Authors:  C L Harris; N K Rushmere; B P Morgan
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

6.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

Review 7.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

8.  Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies.

Authors:  S M Hanna; G T Williams; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

9.  Loxosceles spider venom induces metalloproteinase mediated cleavage of MCP/CD46 and MHCI and induces protection against C-mediated lysis.

Authors:  Carmen W Van Den Berg; Rute M Gonçalves De Andrade; Fabio C Magnoli; Kevin J Marchbank; Denise V Tambourgi
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

10.  Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.

Authors:  Takashi Miwa; Lin Zhou; Michael A Maldonado; Michael P Madaio; Robert A Eisenberg; Wen-Chao Song
Journal:  J Immunol       Date:  2012-10-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.